This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Click here for VYNDAQEL®▼ (tafamidis) Prescribing Information.
As of 19th June 2024, NICE recommends Vyndaqel (tafamidis) as an option for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.1
Tafamidis is only recommended if the company provides it according to the commercial arrangement.
To view the advice in full, visit the NICE Website.
Access to Vyndaqel on the NHS in England
NHS funding for Vyndaqel has been in place since NICE issued the positive Final Draft Guidance, meaning it has been available for use in eligible patients in England since 13th May 2024. This interim funding is made possible through the Innovative Medicines Fund (IMF).2 Funding will switch from the IMF to routine commissioning 30 days after the Final Guidance, which will be the 19th July 2024.
Initially Vyndaqel will be prescribed to eligible adult patients with ATTR-CM by the National Amyloidosis Centre (NAC). To learn more about the referral pathways for your patients get in touch with your local Pfizer Healthcare Partnership Manager.
Access to Vyndaqel on the NHS in Wales
In Wales, the NHS will provide funding to implement the NICE guidance by 12th July 2024.1
NICE = National Institute of Health and Care Excellence ; NHS = National Health Service
References:
Learn about the efficacy of VYNDAQEL in patients with ATTR-CM
To discuss the referral pathways for your patients get in touch with your local Pfizer Healthcare Partnership Manager here.
Learn more about Vyndaqel, the first and only treatment option for adult patients with ATTR-CM.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024